Geron Corp. (GERN), a Menlo Park, California-based biotechnology company, gained the the most in almost two months after a report on the website Seeking Alpha touted the company’s cancer drugs under development.
Geron rose 15 percent to $1.97 at 2:06 p.m. New York time in its biggest intraday advance since June 22. The shares (GERN) lost 38 percent over the last 12 months through yesterday.
